|
MONTREAL, QUEBEC--(Marketwired - April 3, 2015) - Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company"), a leading Canadian specialty pharmaceutical company, announced today that it has committed to invest $10 million in HarbourVest Canada Growth Fund. L.P. ("HarbourVest Fund"). This investment is consistent with Knight's strategy to leverage proven life science funds to help secure innovative pharmaceuticals for Canada and select international markets. Similar to the Teralys Capital Innovation Fund LP, the HarbourVest Fund is part of the Government of Canada's Venture Capital Action Plan. |
